Skip to main content
Equibles
TNGX logo

TNGX · Tango Therapeutics, Inc.

Track TNGX — free

Use TNGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.78 +0.41 (+1.75%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$3.94B
Shares
168.61M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.78 Open$23.72 Day$23.19–24.63 52W close$6.53–32.90 Avg vol 30d2.2M Short int42.6M · 25.3% float · 19.7d Short vol47% DataSep 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$53.81M
Trailing 12 months
Net income (TTM)
−$123.72M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-253.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.01B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.6%
Year over year · more shares
Price change (1Y)
+267.5%
Trailing year
Short interest
25.3%
Latest settlement · 19.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +20%
above
Price vs 50-day avg −10%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 65%
mid-range
Momentum
relative strength
Strong
1-month return −7%
trailing
6-month return +22%
trailing
YTD return +168%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $26 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+28% holders QoQ · +78 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
25.28% of float · ▼ -1.3% MoM · 19.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
249 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
Revenue growth +48%
Y/Y
EPS growth +27%
Y/Y
Free cash flow $-139.9M
Quant / Vol
risk profile
Very High
Volatility 101%
annualized · 1-yr
Max drawdown −32%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+20% Bullish
Price vs 50-day avg
−10% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
65% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $26 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+28% holders QoQ · +78 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
25.28% of float · ▼ -1.3% MoM · 19.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
249 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $24 · 65% Range high $33
vs 200-day avg +20% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TNGX
Tango Therapeutics, Inc.
this stock
$3.94B +168.4% +48.3% — 25.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
249
% held
127.2%
Net QoQ
+34.1M sh
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
220
View
Short & Settlement
Short Interest Falling
Shares short
42.6M
Days to cover
19.7d
Change
-558.6K sh
View
Short Volume
Short vol %
47%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
94.6K
Value
$2.6M
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
46.4%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$62.4M
Net income (FY)
$-101.6M
EPS diluted
$-0.87
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
18
View
Proposed Sales
Value
$2.2M
Shares
81.0K
Filed
Aug 3, 2026
View
Exempt Offerings
Offering
$15.0M
Filed
Oct 28, 2025
View
Earnings & Events
Earnings Calls
Last call
Sep 9, 2026
View
Investor Relations
Latest news
Tango Therapeutics Announces Indu…
Published
Sep 3, 2026
View

Performance

5D 20D 120D MTD YTD
TNGX +4.5% -7.3% +22.5% +4.1% +168.4%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +5.6% -5.5% +4.6% +4.5% +156.3%
Key facts CIK 1819133 CUSIP 87583X109 13F (30d) 147 filings 147 filers Visit website Investor relations